600721 百花医药
2026/09 - 九个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)2.0975.2155.6621.889-5.157
总资产报酬率 ROA (%)1.5433.6793.8111.257-3.505
投入资产回报率 ROIC (%)1.7574.2734.5871.551-4.287

边际利润分析
销售毛利率 (%)43.99445.52951.18849.03739.918
营业利润率 (%)8.34211.3949.6014.862-8.786
息税前利润/营业总收入 (%)8.19311.1069.1944.229-9.258
净利润/营业总收入 (%)7.29610.47810.7533.513-9.928

收益指标分析
经营活动净收益/利润总额(%)170.633176.263251.468413.100-82.173
价值变动净收益/利润总额(%)8.377-16.5229.14211.860-0.034
营业外收支净额/利润总额(%)0.326-0.187-0.464-8.9464.282

偿债能力分析
流动比率 (X)2.3732.2911.8871.8311.749
速动比率 (X)2.2222.1681.5641.4261.232
资产负债率 (%)25.83826.94431.93833.46433.410
带息债务/全部投入资本 (%)10.76811.34214.76712.72811.984
股东权益/带息债务 (%)780.094736.745543.623642.967687.595
股东权益/负债合计 (%)287.020271.136213.107198.825199.308
利息保障倍数 (X)-46.317-41.735-25.331-18.028117.429

营运能力分析
应收账款周转天数 (天)150.15995.34845.45517.45119.092
存货周转天数 (天)67.945110.700214.662262.317294.099